Xintela’s goal is to create significant medical advances in the fields of regenerative medicine and cancer, with particular focus on the treatment of cartilage damage and brain tumours.
Xintela AB is a Swedish biomedical company working in the fields of regenerative medicine and cancer, with particular focus on cartilage damage and brain tumours.
The key to Xintela’s operations is the company’s patented marker technology XINMARK®. Xintela’s markers are specific proteins which work as ”recognition flags” on the surface of certain cells. The markers make it possible to identify and select certain types of stem cells which can develop into cartilage cells. Thus, Xintela can provide a unique way of ensuring the quality of stem cells to be used in repairing damaged cartilage. XINMARK® technology also makes it possible to detect certain tumour cells and target a treatment to those cells to slow the tumour growth.
Xintela was founded in 2009 by the company’s CEO Evy Lundgren-Åkerlund. The company’s operations are based on many years of research and development undertaken by Evy and her team at the University of Lund and in Cartela AB.
In 2013, Xintela initiated its research and development operations with a focus on developing stem cell products for the repair of damaged cartilage. In 2014, research and development work in the field of brain tumour treatment was initiated.
Xintela has a broad and strong patent portfolio, including over 50 approved patents in important markets such as Australia, Europe, USA, Canada and Japan.
Xintela’s management team and Board have extensive experience from the Life Sciences industry, covering research and development of medical products in both preclinical and clinical phases. Also, the Board has broad experience within the field of regenerative medicine and possesses a wealth of knowledge and competence in the fields of economics and law.
Experience: Xintela’s founder. Extensive experience in biomedical research and development. Has previously held senior positions in both academia and industry. Founded Cartela AB and was CEO and Head of Research from 2000-2007. Was Director of Operations/CEO of Ideon Bioincubator/Lund Life Science Incubator from 2008-2012.
No current assignments.
Previous assignments: Board member of Xintela AB.
No. of shares: 4,134,500
Not independent in relation to the Company and its management or by major shareholders.
Experience: Has held several positions as CFO, both in Sweden and abroad, and has been operating through his own consulting firm BioFinans AB for over 15 years.
Current assignments: CEO of BioFinans AB, CFO of AcouSort AB (Publ) and ImmuneBiotech AB. Member of the board of Targinta AB (Publ).
Previous assignments: CFO of A1M Pharma AB.
No. of shares: 73,466
Not independent in relation to the Company and its management, but independent of major shareholders.
Experience: Extensive experience in pharmaceuticals, biotech and medtech.
Current assignments: Chairman of the Board of Saga Diagnostics AB, Monocl AB and Immune Biotech Medical Sweden AB. Partner of Business Research Life Sciences Ltd. CEO of Stanbridge Corporation BVBA. Advisor to Aquilion AB.
Previous assignments: CEO of Pulsetten AB, which divested DuoCort Pharma AB to ViroPharma Inc. in 2011, Board member of Dermafol AB, Maas Biolab LLC (US) and OBV Freehold Limited. Chairman of the Board of NeuroVive Pharmaceutical AB, A1M Pharma AB and AcuCort AB.
No. of shares: 608,300
Not independent in relation to the Company and its management, but independent of major shareholders.
Experience: Extensive experience of international business development in LifeScience, as well as a solid background in biomedical research including experience as a research group leader focusing on medical microbiology and immunology.
Current assignments: Chairman of the Board of Targinta AB.
Previous assignments: Thomas has been Business Development Manager at Invest in Skåne AB and has been a board member at Minervax ApS, as well as advisor to Enzymatica AB.
No. of shares: 0
Not independent in relation to the Company and its management, but independent of major shareholders.
Experience: Extensive experience in pharmaceuticals, biotech and medtech.
Current assignments: Chairman of the Board of Saga Diagnostics AB, Monocl AB and Immune Biotech Medical Sweden AB. Partner of Business Research Life Sciences Ltd. CEO of Stanbridge Corporation BVBA. Advisor to Aquilion AB.
Previous assignments: CEO of Pulsetten AB, which divested DuoCort Pharma AB to ViroPharma Inc. in 2011, Board member of Dermafol AB, Maas Biolab LLC (US) and OBV Freehold Limited. Chairman of the Board of NeuroVive Pharmaceutical AB, A1M Pharma AB and AcuCort AB.
No. of shares: 608,300
Not independent in relation to the Company and its management, but independent of major shareholders.
Experience: Extensive experience in cell therapy. Sven is a surgeon with orthopaedic specialist training with many years’ experience of successful development and commercialisation of cell and gene therapy products from senior positions in the pharmaceutical industry, including Genzyme, Sanofi Biosurgery and GlaxoSmithKline. Sven was also responsible for medical and regulatory issues in cell therapy at Geistlich Pharma. He maintains his clinical expertise in the National Health Service (NHS) in the UK.
Current assignments: Sven is a Board member as well as Chief Medical Officer (CMO) and Chief Operating Officer (COO) of Xintela. Sven is also Chairman of the Board of Sven Kili Consulting Ltd, and Board member of CCRM and SCB and on the Scientific Advisory Board of LGC. Previous assignments: Vice-President and Head of Cell & Gene Therapy Development in GlaxoSmithKline.
No. of shares: 330,427
Not independent in relation to the Company and its management, but independent of major shareholders.
Experience: Extensive experience in drug development at Pharmacia, Astra, AstraZeneca, Biovitrum, Sobi and Orexo. Peter has also been a professor at the Faculty of Pharmacy, Uppsala University.
Current assignments: Currently working as a consultant in the pharmaceutical sector and as a board member. Board member of Xbrane BiopharmaAB and Edman Life Science AB.
Previous assignments: Chief Scientific Officer and Head of R&D at Orexo AB. Board member of Biolopox AB.
No. of shares: 15,000
Independent in relation to both the Company and its management as well as to major shareholders.
Experience: Advisor to the life sciences industry. Previously employed as Global head of AstraZeneca’s Clinical Development, and Global head of AstraZeneca’s Pharmaceutical and Analytical Research and Development.
Current assignments: Board member of Mevia AB, T-bolaget AB, Aqilion AB, Xbrane Biopharma AB, Histolab Products AB and Winkon holding AB.
Previous assignments: Swecure AB and Adenovir Pharma AB.
No. of shares: 60,000
Independent in relation to both the Company and its management as well as to major shareholders.
An important part of Xintela’s business strategy is to collaborate with leading research groups and other companies. Through these collaborations, Xintela can both create interest for the company’s technology and, at the same time, generate income through licencing. Xintela has already initiated several national and international collaborations with players in the fields of regenerative medicine and cancer.
There are currently no open positions but we are always interested in receiving spontaneous applications. If you believe you can contribute new competencies and energy to our dynamic team, send your CV to evy@xintela.se.
